OncoMatch/Clinical Trials/NCT07232290
Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera
Is NCT07232290 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including Flonoltinib 75mg and Flonoltinib 100mg for polycythemia vera (pv).
Treatment: Flonoltinib 75mg · Flonoltinib 100mg · Flonoltinib 125mg · Extended Phase Dose Group — This trial adopts an open, randomized, parallel controlled, multicenter clinical trial design planning to enroll patients with polycythemia vera who are resistant/intolerant to hydroxyurea or interferon. The study divided into two stages: dose exploration stage: three dose groups are set, with three subjects in each group, totally nine subjects in each group; Dose expansion stage: Based on the safety, efficacy, and pharmacokinetic results of the comprehensive dose exploration stage, 2-3 dose groups are planned to be selected for dose expansion stage.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Myeloproliferative Neoplasm
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: hydroxyurea or interferon
resistant/intolerant to hydroxyurea or interferon treatment
Cannot have received: splenectomy
Patients who have undergone splenectomy or splenic radiotherapy in the past
Cannot have received: splenic radiotherapy
Patients who have undergone splenectomy or splenic radiotherapy in the past
Lab requirements
Blood counts
neutrophil count >= 1.0 × 10^9/L, platelet count >= 100 × 10^9/L and <= 1000 × 10^9/L
Kidney function
Serum creatinine <= 1.5 × ULN
Liver function
ALT and AST <= 2.5 × ULN; TBIL <= 2.0 × ULN
neutrophil count >= 1.0 × 10^9/L, platelet count >= 100 × 10^9/L and <= 1000 × 10^9/L; ALT and AST <= 2.5 × ULN; TBIL <= 2.0 × ULN; Serum creatinine <= 1.5 × ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07232290 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior splenectomy, splenic radiotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages